Download
s00393-021-00976-7.pdf 893,03KB
WeightNameValue
1000 Titel
  • Patientensicherheit in der Rheumatherapie
1000 Titelzusatz
  • Patient safety in the treatment of rheumatic diseases
1000 Autor/in
  1. Sierocinski, Elizabeth |
  2. Angelow, Aniela |
  3. Mainz, Armin |
  4. Walker, Jochne |
  5. Chenot, Jean-François |
1000 Erscheinungsjahr 2021
1000 Publikationstyp
  1. Artikel |
1000 Online veröffentlicht
  • 2021-03-11
1000 Erschienen in
1000 Quellenangabe
  • 80(5):418-424
1000 Copyrightjahr
  • 2021
1000 Lizenz
1000 Verlagsversion
  • https://doi.org/10.1007/s00393-021-00976-7 |
  • https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8189943/ |
1000 Publikationsstatus
1000 Sprache der Publikation
1000 Abstract/Summary
  • Background!#!Methotrexate (MTX) is the most commonly prescribed disease-modifying drug in the treatment of rheumatic diseases. Regular laboratory testing is recommended to recognize side effects, such as hepatotoxicity and myelotoxicity as well as decreases in renal function that may cause toxic MTX accumulation. Additionally, folic acid is recommended as prophylaxis against specific side effects. In this study we investigated whether laboratory monitoring and prescription of folic acid took place according to published recommendations.!##!Material and methods!#!Claims data from the statutory health insurance from 1 January 2009 to 31 December 2013 were retrospectively analyzed. A total of 40,087 adults with a rheumatic diagnosis (ICD10 codes M05-M18), no malignant disease and no previous MTX prescription within 12 months were extracted from the InGef (Institute for Applied Health Research in Berlin, formerly Health Risk Institute) research database. The frequency of recommended laboratory testing, appointments with rheumatologists and the prescription of folic acid prophylaxis were investigated.!##!Results!#!Of the patients 12,451 began treatment with MTX in the observation period. Between 42% and 46% of recommended blood counts, liver values and kidney function tests and 14% of urinalyses were performed according to recommendations. Of the patients 84% were seen regularly by a rheumatologist and 74% received a prescription for prophylactic folic acid. Serious conditions potentially resulting from MTX treatment were observed in 0.7-3.5 cases/1000 person years.!##!Discussion!#!Laboratory monitoring in the context of MTX treatment is carried out less frequently than recommended in the literature. Potential MTX-associated serious complications are rare from a practice perspective. On the one hand solutions are needed for a better coordination of laboratory monitoring. On the other hand more empirical evidence is needed regarding the benefits of laboratory monitoring and the appropriate intervals thereof.
1000 Sacherschließung
lokal Drug monitoring
lokal Methotrexate
lokal Rheumatic Diseases/drug therapy [MeSH]
lokal Medikamentenmonitoring
lokal Rheumatic Diseases/diagnosis [MeSH]
lokal Adult [MeSH]
lokal Pharmacovigilance
lokal Humans [MeSH]
lokal Arthritis, Rheumatoid/drug therapy [MeSH]
lokal Guidelines
lokal Retrospective Studies [MeSH]
lokal Pharmakovigilanz
lokal Adverse events
lokal Originalien
lokal Laboratories [MeSH]
lokal Patient Safety [MeSH]
lokal Unerwünschte Arzneimittelwirkungen
lokal Methotrexate/adverse effects [MeSH]
lokal Handlungsempfehlungen
lokal Methotrexat
lokal Antirheumatic Agents/adverse effects [MeSH]
1000 Liste der Beteiligten
  1. https://orcid.org/0000-0003-3679-671X|https://orcid.org/0000-0003-1027-231X|https://frl.publisso.de/adhoc/uri/TWFpbnosIEFybWlu|https://orcid.org/0000-0002-7838-7829|https://orcid.org/0000-0001-8877-2950
1000 Hinweis
  • DeepGreen-ID: ef7d3a7417ec4fba82842db23f4b15e6 ; metadata provieded by: DeepGreen (https://www.oa-deepgreen.de/api/v1/), LIVIVO search scope life sciences (http://z3950.zbmed.de:6210/livivo), Crossref Unified Resource API (https://api.crossref.org/swagger-ui/index.html), to.science.api (https://frl.publisso.de/), ZDB JSON-API (beta) (https://zeitschriftendatenbank.de/api/), lobid - Dateninfrastruktur für Bibliotheken (https://lobid.org/resources/search)
1000 Label
1000 Dateien
1000 Objektart article
1000 Beschrieben durch
1000 @id frl:6450832.rdf
1000 Erstellt am 2023-05-11T11:12:00.764+0200
1000 Erstellt von 322
1000 beschreibt frl:6450832
1000 Zuletzt bearbeitet Fri Oct 20 10:25:01 CEST 2023
1000 Objekt bearb. Fri Oct 20 10:25:01 CEST 2023
1000 Vgl. frl:6450832
1000 Oai Id
  1. oai:frl.publisso.de:frl:6450832 |
1000 Sichtbarkeit Metadaten public
1000 Sichtbarkeit Daten public
1000 Gegenstand von

View source